SHP2 as a therapeutic target

In this article, we explored the potential of SHP2, a key signaling phosphatase, as a therapeutic target in cancer treatment—particularly in overcoming resistance to immune checkpoint therapies. By reviewing current research and combinatorial strategies, the study highlights how inhibiting SHP2 can disrupt cancer-promoting pathways and re-sensitize tumors to immunotherapy. The paper emphasizes SHP2’s central role in both tumor and immune cells, presenting it as a promising druggable node for future targeted therapies.